The Role of CA‐125 in the Management of Ovarian Cancer

The 4th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup was held in Vancouver, Canada, in June 2010. Representatives of 23 cooperative research groups studying gynecologic cancers gathered to establish international consensus on issues critical to the conduct of large randomized trials. Group C, 1 of the 3 discussion groups, examined recurrent ovarian cancer, and we report the consensus reached regarding 4 questions. These included the following: (1) What is the role of cytoreductive surgery for recurrent ovarian cancer? (2) How do we define distinct patient populations in need of specific therapeutic approaches? (3) Should end points for trials with recurrent disease vary from those of first-line trials? (4) Is CA-125 progression alone sufficient for entry/eligibility into clinical trials?

Download Full-text

Role of Extended Chemotherapy in Advanced Ovarian Cancer Patients with High Posttreatment Serum CA-125 Levels

Gynecologic and Obstetric Investigation ◽

10.1159/000322438 ◽

2011 ◽

Vol 72 (1) ◽

pp. 50-54 ◽

Cited By ~ 2

Author(s):

Sokbom Kang ◽

Tae-Joong Kim ◽

Sang-Soo Seo ◽

Byoung-Gie Kim ◽

Duk-Soo Bae ◽

...

Keyword(s):

Ovarian Cancer ◽

Cancer Patients ◽

Advanced Ovarian Cancer ◽

Ca 125

Download Full-text

Role of preoperative CA-125 levels in predicting the DFS and OS in epithelial ovarian cancer

International Journal of Reproduction Contraception Obstetrics and Gynecology ◽

10.18203/2320-1770.ijrcog20175423 ◽

2017 ◽

Vol 7 (1) ◽

pp. 69

Author(s):

Shashidhar V. Karpurmathrmath ◽

Velukuru Sai Vivek ◽

Manjunath I. Nandennavar ◽

Veerandra Angadi ◽

Annalakshmi Sekar

Keyword(s):

Ovarian Cancer ◽

Overall Survival ◽

Survival Rates ◽

Disease Free Survival ◽

Stage Iv ◽

Significant Rise ◽

Stage I ◽

Ca 125 ◽

Screening Methods

Background: Ovarian cancer has the highest mortality rate among all the other gynaecologic malignancies. Stage I cancer treated with surgery and adjuvant chemotherapy report a 5-year overall survival of 95% while this value significantly drops to 25% in stage IIIC and IV patients. Unfortunately, effective screening methods to detect the early cancer are yet to be identified.Methods: All the patients diagnosed to have epithelial ovarian carcinoma from January 2012 to December 2014 at our center with pre-treatment CA-125 levels were included in this retrospective study. Disease free survival and overall survival were tabulated either by telephonic conversation or on a regular follow up visit to the hospital.Results: Among the 69 patients enrolled 38% of the patients were in the age group of 50-60 years. 58% of patients had stage 3 disease up front. mean CA-125 levels were lowest in patients with stage I disease and the highest in stage IV disease with a statistically significant rise in CA-125 levels with the stage of disease. Only 52% of the patients completed the treatment as per protocol. There was a significant negative co relation between the CA-125 levels and survival rates in both the sub groups of patients who received complete and incomplete treatment respectively.Conclusions: In the present study we would like to conclude that pre-operative CA-125, which has already been included in the screening algorithms like ROCA, has a greater potential to become a prognostic marker. Present study is limited by the small number of patient’s and thus larger multi centric studies with better randomization could establish the role of CA-125 as a prognostication marker.

Download Full-text

The Role of Akt2 and CA-125 Serum Levels as Predictors for Successful Cytoreduction in Epithelial Ovarian Cancer Surgery

European Journal of Gynaecological Oncology ◽

10.31083/j.ejgo.2020.05.2116 ◽

2020 ◽

Vol 41 (5) ◽

pp. 739

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Serum Levels ◽

Cancer Surgery ◽

Ca 125

Download Full-text

The Role of 18F-FDG PET/CT in Detecting Ovarian Cancer Recurrence in Patients with Elevated CA-125 Levels

Molecular Imaging and Radionuclide Therapy ◽

10.4274/mirt.galenos.2018.00710 ◽

2019 ◽

Vol 28 (1) ◽

pp. 8-14 ◽

Cited By ~ 3

Author(s):

Arzu Cengiz ◽

Zehra Pınar Koç ◽

Pelin Özcan Kara ◽

Yakup Yürekli

Keyword(s):

Ovarian Cancer ◽

Fdg Pet ◽

Cancer Recurrence ◽

Ca 125 ◽

Pet Ct ◽

Fdg Pet Ct

Download Full-text

The potential role of serum CA 125 in an ultrasound-based screening program for familial ovarian cancer

International Journal of Gynecology & Obstetrics ◽

10.1016/0020-7292(94)90606-8 ◽

1994 ◽

Vol 47 (3) ◽

pp. 321-321

Author(s):

T.H. Bourne ◽

S. Campbell ◽

K. Reynolds ◽

J. Hampson ◽

L. Bhatt ◽

...

Keyword(s):

Ovarian Cancer ◽

Potential Role ◽

Screening Program ◽

Ca 125 ◽

Familial Ovarian Cancer

Download Full-text

The Value of CA 125 and CA72-4 in Management of Patients with Epithelial Ovarian Cancer

Disease Markers ◽

10.1155/1998/738321 ◽

1998 ◽

Vol 14 (3) ◽

pp. 155-160 ◽

Cited By ~ 16

Author(s):

Salah T. Fayed ◽

Samira M. Ahmad ◽

Samar K. Kassim ◽

Ali Khalifa

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Residual Disease ◽

Ca 125 ◽

Platinum Based Chemotherapy ◽

Pelvic Masses ◽

Radiometric Assay ◽

Normal Women

The role of the tumor markers CA125 and CA72-4 has been evaluated in the diagnosis and management of ovarian cancer. Both markers were measured in 30 patients with proven epithelial ovarian cancer, 30 patients with benign pelvic masses and 30 normal women. CA125 and CA72-4 were measured using the luminometric immunoassay and immuno-radiometric assay respectively. All patients with ovarian cancer were submitted to surgical staging and cytoreduction followed by adjuvant platinum based chemotherapy for 3–6 courses. Fixing the specificity at 95%, CA125 had a sensitivity of 76.7% at a cut-off 85u/ml while CA72-4 had a sensitivity of 70% at a cut-off 8.5 u/ml. The combination of CA72-4 with CA125 increased the sensitivity to 95% while fixing the specificity at 95%. Among seven cases with stage I and II ovarian cancer five cases had CA125 level below 85 U/ml, three patients out of them had CA72-4 above 8.5 U/ml. CA 72-4 could reflect the residual disease following cytoreduction and could improve the detection of relapse by CA125.Conclusion: CA72-4 could complement the standard tumor marker CA125 both in diagnosis and follow up of patients with epithelial ovarian cancer.

Download Full-text

The Role of HE4 in Ovarian Cancer Follow-up: A Review

International Journal of Gynecological Cancer ◽

10.1097/igc.0000000000000218 ◽

2014 ◽

Vol 24 (8) ◽

pp. 1359-1365 ◽

Cited By ~ 23

Author(s):

Elisa Piovano ◽

Lorenza Attamante ◽

Chiara Macchi ◽

Camilla Cavallero ◽

Cesare Romagnolo ◽

...

Keyword(s):

Ovarian Cancer ◽

Cancer Recurrence ◽

Ca 125 ◽

Prognostic Role ◽

Independent Predictive Factor ◽

Secondary Cytoreductive Surgery ◽

Number Of Patients ◽

Predictive Role

ObjectiveThe aim of this review was to analyze the state of the art about HE4 and follow-up in patients treated for ovarian cancer.MethodsA literature search was conducted in the MEDLINE database using the key words “HE4” and “ovarian cancer” and “recurrence” or “relapse” or “follow up.”ResultsSeven of 28 clinical studies were selected. Four studies were prospective, and all of them were based on a small number of patients (8–73 women). A failure of HE4 levels to normalize at completion of standard therapy may indicate a poor prognosis, thus suggesting the need of a closer follow-up. Moreover, HE4 showed better sensibility and specificity in the diagnosis of ovarian cancer recurrence with respect to CA-125, being also an earlier indicator of the relapse with a lead time of 5 to 8 months. HE4 showed a better performance in this setting if performed in association with other markers (CA-125, CA-72.4). HE4 seems to be an independent predictive factor for the surgical outcome at secondary cytoreductive surgery and to maintain its prognostic role even after the recurrence.ConclusionsThese preliminary data start to suggest a superiority of HE4 over CA-125 in the detection of ovarian cancer recurrence. Moreover, the prognostic role of HE4 could help clinicians to personalize the follow-up program, whereas its predictive role could be useful to plan the treatment of the relapse. The role of HE4 in ovarian cancer follow-up deserves to be further investigated in prospective randomized multicentric studies.

Download Full-text